Zou et al. observed downregulated MEG3 expression in NAFLD patients, which was in line with previous preclinical studies showing that MEG3 was downregulated in in vitro and in vivo models of NAFLD and was negatively related to lipogenesis-related genes, and that boosting MEG3 expression alleviated HFD-induced NAFLD progression [40,63]. The gene discussed is MEG3; the disease is metabolic dysfunction-associated steatotic liver disease.